/
Infectious Disease
Meningioma
23
Pipeline Programs↗
34
Active Trials↗
13
Companies Involved↗
Meningioma is an emerging landscape with 23 programs across 13 companies. The most active players are Shanghai Runshi Pharmaceutical Technology Co., Ltd.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical6
Phase 15
Phase 212
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
70%
Small molecule
14 of 20 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 20 classified programs, each share of the total. Modality classified for 91% of 23 pipeline programs.
Analysis
Trial Status
72
clinical trials
Completed25 · 35%
Recruiting21 · 29%
Active, not recruiting10 · 14%
Unknown status6 · 8%
Terminated5 · 7%
Not yet recruiting3 · 4%
Other2 · 3%
Clinical Trials
Trial Activity
72 trials
Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures
Recruiting·—·Phase 1·NCT07493447·30 enrolled
Progressive/Recurrent Intracranial Meningioma Treated With SSTR-Targeted Alpha Emitter RYZ101 (PRIMe-STAR)
Recruiting·—·Preclinical·NCT07150806·30 enrolled
Abemaciclib in Newly Diagnosed Meningioma Patients
Recruiting·—·Phase 2·NCT05940493·72 enrolled
Page 1 of 5
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)